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Abstract
The human aldehyde dehydrogenase (ALDH) superfamily consists of at least 19 enzymes that 
metabolize endogenous and exogenous aldehydes. Currently, there are no commercially available 
inhibitors that target ALDH1A1 but have little to no effect on the structurally and functionally 
similar ALDH2. Here we present the first human ALDH1A1 structure, as the apoenzyme and in 
complex with its cofactor NADH to a resolution of 1.75 Å and 2.1 Å, respectfully. Structural 
comparisons of the cofactor binding sites in ALDH1A1 with other closely related ALDH enzymes 
illustrate a high degree of similarity. In order to minimize discovery of compounds that inhibit 
both isoenzymes by interfering with their conserved cofactor binding sites, this study reports the 
use of an in vitro, NAD+-independent, esterase-based high-throughput screen (HTS) of 64,000 
compounds to discover novel, selective inhibitors of ALDH1A1. We describe 256 hits that alter 
the esterase activity of ALDH1A1. The effects on aldehyde oxidation of 67 compounds were 
further analyzed, with 30 selectively inhibiting ALDH1A1 compared to ALDH2 and ALDH3A1. 
One compound inhibited ALDH1A1 and ALDH2, while another inhibited ALDH1A1, ALDH2, 
and the more distantly related ALDH3A1. The results presented here indicate that this in vitro 
enzyme activity screening protocol successfully identified ALDH1A1 inhibitors with a high 
degree of isoenzyme selectivity. The compounds identified via this screen plus the screening 
methodology itself represent a starting point for the development of highly potent and selective 
inhibitors of ALDH1A1 that may be utilized to better understand the role of this enzyme in both 
normal and disease states.
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1. Introduction
The aldehyde dehydrogenase (ALDH) superfamily of enzymes primarily catalyze the 
NAD(P)+-dependent oxidation of an aldehyde to its corresponding carboxylic acid[1]. The 
human genome has at least 19 ALDHs. A primary function of the ALDH1A subfamily 
(ALDH1A1, ALDH1A2, and ALDH1A3), whose members share over 70% protein 
sequence identity, is the oxidation of retinaldehyde to retinoic acid, a critical regulator in a 
number of cell growth and differentiation pathways. Other aldehydes also serve as substrates 
for ALDH1A1, including acetaldehyde during ethanol metabolism, 3,4-
dihydroxyphenylacetaldehyde (DOPAL) in dopamine metabolism, and (±)-4-hydroxy-2E-
nonenal (4-HNE), a toxic by-product of oxidative stress pathways. ALDH1A1 has been 
associated with a number of diseases. Down-regulation of ALDH1A1 has been reported in 
Parkinson’s disease, possibly due to the build-up of the neurotoxic aldehyde DOPAL in 
dopamine metabolism[2, 3]. ALDH1A1 knockout mice are able to resist diet-induced 
obesity[4], while rodents given the nonselective ALDH1A1 inhibitor citral also exhibit 
reduced weight gain[5], indicating that ALDH1A1 is playing a role in obesity and/or 
adipogenesis. Up-regulation of ALDH1A1 is a biomarker for both normal and cancer stem 
cells, but the role of ALDH1A1 in establishing and/or maintaining stem cells is not 
known[6–9]. ALDH1A1 and ALDH3A1 have long been linked to cancer drug resistance 
due to their roles in the metabolism of the anticancer agent cyclophosphamide[10]. It is 
evident that ALDH1A1 is involved in a number of biological processes, but its contributions 
to both normal and disease states, including retinoid-dependent processes, are not clearly 
understood. The development of selective activators and inhibitors of ALDH1A1 would 
provide chemical tools to help decipher the role of this enzyme. However, at this time there 
are no commercially available, ALDH1A1-selective modulators.
The development of compounds that selectively target ALDH1A1 has proven to be difficult 
as the ALDH superfamily of enzymes shares many common structural and mechanistic 
features. These members generally function as homodimers or homotetramers, with each 
subunit containing three structural domains, a catalytic domain, a cofactor binding domain, 
and an oligomerization domain. The NAD(P)+ binding domain is a Rossmann-fold, a 
nucleotide binding site that consists of two sets of parallel beta sheets and alpha helices. The 
Rossmann-fold structure motif is found in the NAD+ binding domains of multiple 
dehydrogenase families, including ALDHs, lactate dehydrogenases, alcohol 
dehydrogenases, and glyceraldehyde-3-phosphate dehydrogenase[11–13]. There are 
differences in the Rossmann fold between ALDH and other oxidoreductases that could 
possibly be exploited for the development of small molecule modulators of various ALDH 
isoenzymes compared to other NAD+-binding enzyme families[14]. However, there exists 
much structural similarity in the NAD+- binding site within the ALDH family and the 
development of selective modulators that target this site may present difficulties.
A number of ALDH’s, including ALDH1A1 also possess esterase activity. Based on the 
ALDH2 sequence, site-directed mutagenesis has shown that Cys-302 is the essential 
nucleophile for both the esterase and dehydrogenase reaction, with Glu-268 acting as the 
general base to activate Cys-302[15, 16]. The proposed catalytic steps for both the 
dehydrogenase and esterase reactions have been recently reviewed[17], although minor 
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details still need to be resolved including the roles of second sphere residues in assisting 
proton transfer to solvent[18, 19]. The use of common active site residues for the two 
reactions makes it likely that modulators of the esterase reaction would also modulate 
aldehyde oxidation activity. In support of this hypothesis, the ALDH2 activator Alda-1 
activates both the esterase and dehydrogenase activity of the enzyme and daidzen inhibits 
both reactions[13, 20, 21]. An additional advantage of the esterase reaction is that it does not 
require the cofactor NAD+ to be present, and so allows the screen to be less influenced by 
compounds binding to this site.
The human ALDH1 family, which shares over 60% protein sequence identity, is a 
particularly difficult challenge for inhibitor development since it contains the highest 
number of orthologs in the genome at seven (ALDH1A1, ALDH1A2, ALDH1A3, 
ALDH1B1, ALDH1L1, ALDH1L2, and ALDH2). Compounds such as 
diethylaminobenzaldehyde (DEAB) and disulfiram are potent inhibitors of ALDH1A1, with 
IC50’s in the nM range, but both also inhibit ALDH2[17, 22]. DEAB is also a relatively 
potent inhibitor for a number of other ALDH1 family members, although not ALDH1L1 
[22, 23]. An in vitro high throughput screen (HTS) is one method of discovering novel, 
small molecule modulators for a particular enzyme. Typically, the rate of aldehyde oxidation 
by ALDHs is studied by monitoring the formation of NADH at 340 nm on a 
spectrophotometer (molar extinction coefficient of 6220 M−1 cm−1) (Figure 1A). However, 
this approach is not ideal for the screening assay as it is common for compounds in the 
libraries to absorb light in the same wavelength range as NADH and leads to interference in 
this analytical approach. Therefore, another assay design is needed for an ALDH1A1 HTS. 
One approach is to couple aldehyde oxidation to a second reaction that can be monitored by 
either fluorescence or UV/Vis spectrophotometry. For example, the dehydrogenase activity 
of ALDH2 was coupled to the NADH-dependent reduction of resazurin to resorufin to 
discover the ALDH2 activator Alda-1[20]. However, a second approach would be to use the 
inherent esterase activity of ALDH1A1 to identify modulators. The ALDH1A1 ester 
substrate para-nitrophenylacetate (pNPA) is hydrolyzed to p-nitrophenol, which absorbs 
light at 405 nm and can be monitored spectrophotometrically, with minimal interference 
from library compounds (Figure 1B).
In this paper, we used an in vitro esterase assay to identify compounds that modulate 
ALDH1A1 activity but have little to no effect on either ALDH2, an isoenzyme that has 
approximately 70% protein sequence identity with ALDH1A1, or ALDH3A1, a more 
distantly related isoenzyme with 30% protein sequence identity. Comparison of the cofactor 
binding sites of human ALDH1A1 and ALDH2 points to a high degree of similarity, 
suggesting that development of selective modulators that bind at this location would be 
challenging. Use of the esterase assay allowed us to minimize two potential problems: 1) 
identification of compounds that bind to the highly conserved cofactor site, and 2) monitor 
activity at a wavelength with minimal spectral overlap to that of the library compounds. Of 
the 64,000 compounds screened, 256 were identified as modulators of ALDH1A1 esterase 
activity. We examined the dehydrogenase activity and selectivity of 67 hits and nearly half 
selectively inhibited ALDH1A1 dehydrogenase activity. These results indicate that this 
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simple esterase-based in vitro HTS was successful in identifying novel, selective inhibitors 
of ALDH1A1.
2. Materials and Methods
2.1 Materials
All chemicals and reagents including para-nitrophenylacetate, propionaldehyde, NAD+, and 
buffers were purchased from Sigma Aldrich unless where noted otherwise.
2.2 Expression and Purification of ALDH Proteins
ALDH1A1, ALDH2, and ALDH3A1 were prepared as described elsewhere[24–26]. Protein 
used for kinetics was flash frozen in liquid nitrogen and stored at −80°C. ALDH1A1 protein 
used for X-ray crystallography was stored at −20°C in a 50% (v/v) solution with glycerol 
and dialyzed against 10 mM Na+-ACES pH 6.6 and 1 mM dithiothreitol at 4°C. The 
ALDH1A1 protein used for the screen was produced from a cDNA obtained from Dr. Henry 
Weiner containing a known A-to-G SNP at position 72928972 on chromosome 9 (NCBI 
rs1049981), resulting in an Asn-to-Ser missense mutation at protein position 121[27]. This 
SNP has been found in a small percentage of the HapMap-CEU population representing 
Utah residents with Northern and Western European ancestry, but there is no known clinical 
significance to the mutation. The NCBI reference sequence for ALDH1A1 (wild-type) was 
constructed using the forward primer 5′- CTC TAT TCC AAT GCA TAT CTG AAT GAT 
TTA GCA GGC TGC ATC -3′ and its complement, using the QuikChange site-directed 
mutagenesis protocol. Unless where noted otherwise, ALDH1A1 WT protein was used for 
all aldehyde oxidation assays and the X-ray crystallography of the ALDH1A1-NADH 
structure. ALDH1A1-N121S was used for the HTS and the apo-enzyme structure. For the 
kinetic assays, although the enzymes have more activity at a higher pH, a more 
physiologically relevant pH of 7.5 was used for both the HTS and dehydrogenase assays. 
This also kept the spontaneous hydrolysis of the ester substrate to a minimum and allowed 
direct comparison between the esterase and dehydrogenase assays.
2.3 Structural determination of human ALDH1A1
For the apo-enzyme structure, crystals of ALDH1A1 N121S at 3–5 mg/mL concentration 
were equilibrated against a crystallization solution of 100 mM sodium BisTris, pH 6.2–7.0, 
8–12% PEG3350 (Hampton Research), 200 mM NaCl, and 5–10 mM YbCl3 at 25°C. 
Freezing of the crystals occurred in crystallization solution plus 20% (v/v) ethylene glycol. 
For the ALDH1A1-NADH structure, apo-enzyme crystals (WT) were prepared in the same 
manner as ALDH1A1 N121S crystals and were soaked for 2 hours with crystallization 
solution containing 1 mM NAD+. Freezing of the crystals occurred in crystallization 
solution with NAD+ plus 20% (v/v) ethylene glycol. Diffraction data was collected at 
Beamline 19-ID operated by the Structural Biology Consortium at the Advanced Photon 
Source, Argonne National Laboratory. Diffraction data were indexed, integrated, and scaled 
using either the HKL2000 or HKL3000 program suites[28]. The CCP4 program suite[29] 
was used for molecular replacement and refinement, using the sheep ALDH1 structure (PDB 
Code 1BXS) as a model for the apo-ALDH1A1 structure. The Coot molecular graphics 
application[30] was used for model building and the TLSMD (Translation/Libration/Screw 
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Motion Determination) server was used to determine dynamic properties of the protein[31, 
32].
2.4 Esterase based high throughput screen on ALDH1A1
The high throughput screen was performed in 384-well, clear-bottomed plates, monitoring 
the change in absorbance of p-nitrophenol at 405 nm wavelength (molar extinction 
coefficient of 18000 M−1 · cm−1) on a Spectramax plate reader. The chemical library 
consisted of 64,000 compounds from ChemDiv Corp (San Diego, CA) at a final 
concentration of 10 μM. The 50 μL assay contained 730 nM ALDH1A1, 800 μM substrate 
para-nitrophenylacetate (pNPA), 10 μM compound, and 2% DMSO in 25 mM Na+-HEPES, 
pH 7.5 at 25°C. The non-selective ALDH1A1 inhibitor Aldi-1[33] at 25 μM final 
concentration was used as a positive control of ALDH1A1 esterase inhibition in each plate. 
Following a 2 minute incubation of enzyme and compound, the reaction was initiated by 
adding the substrate pNPA and monitored for 7 minutes. A Z-factor for the HTS was 
calculated by comparing the values of ALDH1A1 plus/minus Aldi-1 under the conditions of 
the HTS assay, each at n = 384 to determine the quality of the HTS conditions. A second 
control using no enzyme was also performed to determine whether our control inhibitor 
concentration had nearly 100% inhibition. An activator was defined as having 2-fold or 
higher esterase activity compared to control, while an inhibitor had 50% or less activity. 
After one round of screening, compounds identified as activators and inhibitors were 
rescreened using the same protocol and cutoffs to confirm the initial readings.
2.5 ALDH1A1, ALDH2, and ALDH3A1 aldehyde oxidation activity assays
Hits from the HTS were ordered from ChemDiv to determine if they had any effect on 
aldehyde oxidation and whether they were selective for ALDH1A1 compared to ALDH2 
and ALDH3A1. Dehydrogenase activity of the three isoenzymes were assayed by 
monitoring the production of NADH at 340 nm (molar extinction coefficient of 6220 M−1 · 
cm−1) on a Beckman DU-640 or Cary 300 Bio UV-Vis spectrophotometer for 2 to 3 
minutes. For ALDH1A1 and ALDH2, the reaction contained 100–200 nM enzyme, 200 μM 
NAD+, 100 μM propionaldehyde, and 1% DMSO in 50 mM Na+ BES, pH 7.5 at room 
temperature. For ALDH3A1, the reaction contained 20 nM enzyme, 200 μM NAD+, 300 μM 
benzaldehyde, and 1% DMSO in either 100 mM sodium phosphate or 50 mM Na+ BES at 
pH 7.5 at room temperature. For most compounds, 20 μM concentration was used for the 
selectivity assays. However, due to solubility issues for CM307, 10 μM of compound was 
used. Following a 2 minute incubation of enzyme, compound, and NAD+, the reaction was 
initiated by adding substrate. For compounds with over 60% inhibition at 20 μM, IC50 
values for propionaldehyde oxidation were calculated by varying the concentration of the 
compounds from 0–200 μM under the same conditions as the selectivity assays. Data were 
fit to the four parameter EC50 equation using SigmaPlot (StatSys v12.3).
3. Results
3.1 Structure of human ALDH1A1
X-ray crystallography was used to compare the structure of human ALDH1A1 with other 
members of the ALDH enzyme superfamily. The structure of human ALDH1A1 had not 
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been previously reported (Figure 2 and Table 1, PDB Code 4WJ9). As expected, it is highly 
similar to both the human ALDH2 enzyme (PDB code 3N80), with which ALDH1A1 shares 
about 70% sequence identity, and the sheep ALDH1A1 (PDB code 1BXS), with over 90% 
sequence identity. The structure of ALDH1A1 with NADH was determined to a resolution 
of 2.1 Å (Figure 3 and Table 1, PDB Code 4WB9). A comparison of the respective alpha-
carbons in the structure of the N121S apo-enzyme and those of the wild-type ALDH1A1 
structure complexed with NADH, generated an RMSD of 0.2 Å, consistent with a high 
degree of functional and structural similarity. The side chains of Ser and Asn both form 
similar hydrogen bonding interactions with Tyr297. Although wild-type apo-crystals were 
soaked with NAD+, the cofactor is bound in the hydrolysis position, characteristic of NADH 
binding, in the structure which suggests it could have been reduced via oxidation of PEG 
aldehydes. The hydrolysis conformation observed here is similar to that seen in ALDH2 
(PDB Code 1O02)[25] and the sheep ALDH1A1 (PDB Code 1BXS)[34] with cofactor, with 
the exception of the interaction of Glu-349 with a ytterbium cation bound to the 
pyrophosphate of NADH. Comparison of the structure of ALDH1A1, ALDH2, and 
ALDH3A1 (PDB Code 4L2O) with cofactor illustrates the difficulty of developing selective 
inhibitors for ALDH1A1 that target this site. There is a high degree of similarity between 
the cofactor binding sites of ALDH1A1 and ALDH2 (Figure 4), supporting our hypothesis 
to select an assay independent of the cofactor binding site in order to develop selective 
inhibitors for the ALDH1/2 class of enzymes. ALDH3A1 is the least similar both by 
structural topology and sequence identity, and as expected based on its ability to utilize both 
NAD+ and NADP+, these differences are most obvious near the adenosine ribose and 
pyrophosphate binding site.
3.2 High throughput screen to identify modulators of ALDH1A1 esterase activity
The Z-factor for the HTS comparing ALDH1A1 plus/minus inhibitor (Aldi-1) under 
screening conditions was 0.67 (n = 384), indicating the screen is capable of identifying 
inhibitors from single assays. As shown in Figure 5, there is a clear separation between the 
control reaction containing enzyme and substrate (ES Control) represented in blue, and the 
inhibitor control reaction containing enzyme, substrate plus an ALDH1A1 inhibitor (ESI 
control) represented in red. Also, the average value for ALDH1A1 with control inhibitor 
was similar to the no enzyme, blank control (mean rate of change of 0.70 vs 0.60), 
indicating our inhibition control (25 μM Aldi-1, IC50 = 2.2 μM[33]) strongly inhibited 
ALDH1A1. For the HTS, we used an ALDH1A1 protein with a known SNP at residue 121. 
This N121S “mutant” is the open reading frame cloned by the Weiner group [26] and 
utilized for all their published work on ALDH1A1. The enzyme is active and behaved 
similarly to ALDH1A1 WT (Km of 12 μM vs 15 μM, respectfully, with identical kcat/Km 
values at 2.7 min−1 · μM−1 for the substrate propionaldehyde). The screen used a saturating 
amount of the esterase substrate pNPA (Km = 5μM[35]). Each plate contained a control 
column with enzyme and substrate (ES control) and the average (n = 16) of this intraplate 
control served as the basis to determine whether a compound modified esterase activity. An 
activator was defined as having 2-fold or higher esterase activity compared to this control, 
while an inhibitor had 50% or less activity. Each plate also contained a positive control for 
inhibition (ESI control) using the inhibitor Aldi-1. The initial round of the in vitro es terase-
based screen of 64000 compounds yielded 631 compounds that activated ALDH1A1 and 
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278 compounds that inhibited ALDH1A1. A sample plate from the first round of screening 
is shown in Figure 6, illustrating 3 activators and 1 inhibitor out of 352 compounds tested. 
Following rescreening of the 909 compounds identified in the first round under identical 
conditions, nearly 75% did not meet these same selection criteria during the second, 
validation assay set. After two rounds, the esterase screen identified 241 activators and 15 
inhibitors of ALDH1A1 esterase activity (Supplementary Tables 1 and 2).
3.3 ALDH1A1, ALDH2, and ALDH3A1 aldehyde oxidation activity assays
The 256 compounds were grouped based on structural similarities. From this set of 
compounds, we selected 57 esterase activators and 10 esterase inhibitors and tested their 
ability to alter aldehyde oxidation (Figure 7). Of the 15 esterase inhibitors identified by 
HTS, only eight were commercially available. However, close analogs of three were 
purchased and analyzed, hit 3343–2924 was substituted by 2188–3302 (CM310), hit 
C699-0615 was substituted by C699-0244 (CM306), and hit K788-2754 was substituted by 
K938-0803 (CM307). The effects the hits have on aldehyde oxidation were tested using the 
standard assays performed in our laboratory to study these three ALDH isoenzymes. For 
ALDH1A1 and ALDH2, 100 μM propionaldehyde is near to saturation (ALDH1A1 Km ~15 
μM and ALDH2 Km < 1 μM). For ALDH3A1, the concentration of benzaldehyde used was 
set at its Km. None of the 67 compounds tested activated aldehyde oxidation by ALDH1A1, 
ALDH2, or ALDH3A1 by more than 20%. However, of the 57 esterase activators examined 
at 20 μM concentration, 28 inhibited ALDH1A1 propionaldehyde oxidation at least 50%. Of 
the 10 esterase inhibitors tested at 20 μM concentration, four inhibited ALDH1A1 
propionaldehyde oxidation at least 50%, but two inhibitors (CM302 and CM303) also 
exhibited at least 50% inhibition of ALDH2 and therefore were not selective for ALDH1A1. 
To a limited degree, CM302 also inhibited ALDH3A1 but none of the remaining 66 hits 
altered ALDH3A1 benzaldehyde oxidation more than 20% from control. Based on the 
selectivity assays of 67 esterase hits, 30 compounds selectivity inhibited ALDH1A1 
compared to ALDH2 and ALDH3A1, while two compounds inhibited both ALDH1A1 and 
ALDH2 at least 50% but not ALDH3A1.
IC50 values were determined for compounds that inhibited propionaldehyde oxidation at 
least 60% at 20 μM concentration, with the most potent inhibitors and their IC50 values 
shown in Table 2. Of the 57 esterase activators, 17 were structurally similar (CM022-031, 
CM051-057) with all but one (CM024) inhibiting ALDH1A1 at 20 μM compound 
concentration. Based on IC50 values, the most potent inhibitors selective for ALDH1A1 
were CM038 and two structural analogs, CM053 and CM055, with all three hits having IC50 
values less than 300 nM. CM0302 was a potent inhibitor of both ALDH1A1 and ALDH2, 
with IC50 values of 1.0 ± 0.1 μM and 2.2 ± 0.3 μM, respectfully. To a limited extent, CM302 
also inhibited ALDH3A1, but with an IC50 value greater than 10-fold higher compared to 
ALDH1A1 and ALDH2. In comparison, the nonselective inhibitor Aldi-1, which was used 
as a control during the esterase HTS, has an IC50 value of 2.2 μM[33]. DEAB is a 
nonselective ALDH1 inhibitor used as a control for the ALDEFLUOR Assay (Stemcell 
Technologies, Vancouver, Canada), a flow cytometry assay commonly used to identify stem 
cells based on ALDH activity. DEAB has an IC50 value of approximately 60 nM under these 
same conditions, but is also a potent inhibitor of other ALDH isoenzymes[23].
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Discussion
Comparison of the structures of human ALDH1A1, ALDH2, and ALDH3A1 indicate they 
exhibit a high degree of structural similarity, but demonstrate distinct differences within 
their substrate binding sites. In contrast, their respective coenzyme binding sites are less 
dissimilar, especially between ALDH1A1 and ALDH2 (Figure 4). This supports our 
screening approach to avoid identifying compounds that interact at this location, as they are 
less likely to be selective for ALDH1/2 class members. However, it might be possible to 
utilize this approach for inter-class selectivity (Figure 8).
The esterase screen used in this study was modeled after a previously reported screen for 
ALDH3A1 inhibitors that successfully identified two classes of selective ALDH3A1 
inhibitors capable of increasing mafosfamide sensitivity in cancer cells[26, 36, 37]. By 
adapting this assay to ALDH1A1, we screened a 64,000 compound library and following 
one round of screen, identified over 900 compounds. Rescreening of these compounds under 
identical conditions resulted in 256 confirmed hits that modified ALDH1A1 esterase 
activity. Therefore, the effect on esterase activity of <30% of the identified activators/
inhibitors identified in round one were successfully repeated in round two. Although these 
replicability results may seem low, HTS are inherently noisy to begin with, producing many 
false positives that can be eliminated in the second round. As shown in Figure 5, simply 
calculating the Z-factor produced outliers despite identical conditions within one plate. 
Some reasons for poor replicability include inaccuracies in compound concentration, 
spectral interference from the compounds, errors in robot pipetting, and debris or bubbles in 
the well that interfered with the reading. The second round of screening is designed to 
remove these false positives from consideration, conserving both time and resources. Since 
the HTS identified 256 compounds, the large number of false positives from round one was 
not a concern. We examined the effect on dehydrogenase activity of 67 of these compounds 
and found that 30 selectively inhibited ALDH1A1 compared to ALDH2 and ALDH3A1, 
while 2 inhibited both ALDH1A1 and ALDH2. Therefore, nearly 50% of the esterase 
modifiers identified also altered aldehyde oxidation and almost all of the compounds did so 
selectively for ALDH1A1 compared to two other ALDH’s.
Of the 57 esterase activators tested, none activated the dehydrogenation reaction of 
ALDH1A1, but nearly half inhibited it. The esterase reaction is independent of NAD+, but 
the presence of either NAD+ or NADH will increase the rate of ester hydrolysis, depending 
on assay conditions[35, 38]. The substrate and cofactor binding sites are linked to the active 
site by a tunnel through the enzyme. For ester hydrolysis, the substrate can likely enter the 
active site via either end of this tunnel. To activate esterase activity, it is proposed that 
cofactor binding slows transit of the ester substrate out of the tunnel, increasing the number 
of productive encounters with the active site nucleophile and also possibly by directly 
activating the nucleophile (Figure 2B) [13]. Compounds that function as esterase activators 
but dehydrogenase inhibitors likely bind to the substrate-binding end of this tunnel. In a 
manner similar to activation via cofactor binding, compound binding slows the transit of 
pNPA out of the active site tunnel and increases the likelihood of a productive encounter 
with the active site cysteine. However, the effect these esterase activators have on the 
NAD+-dependent aldehyde oxidation reaction is the opposite. Binding of the compound 
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along with cofactor binding alters access to the active site at both ends and therefore 
depending on the structure of the compound could inhibit dehydrogenase activity. However, 
as seen with the ALDH2 activator Alda-1, a compound that binds at the substrate binding 
end of the active site tunnel could also result in a dehydrogenase activator, depending on 
binding position, location relative to the active site residues and substrate size[13]. It is 
possible that a number of our esterase activators that had no effect on aldehyde oxidation 
acted at the cofactor binding site, activating the esterase reaction like NAD+/NADH. 
However, the levels of NAD+ used in the assays (approximately 4 × KM) might minimize 
their effect on aldehyde oxidation. If a compound did bind at the cofactor site, only an 
extremely potent or covalent modulator would be identified under these conditions.
Of the 241 esterase activators identified, 78 were structural analogs with a common xanthine 
ring core structure. Of these 78 compounds, 17 were tested (CM022-031, CM051-057) and 
16 selectively inhibited dehydrogenase activity of ALDH1A1 with no effect on either 
ALDH2 or ALDH3A1. The esterase HTS also produced 8 other structural groups containing 
between 7 and 20 analogs each. As a consequence, 65% of the esterase hits could be 
classified into 9 structural groups (Table 3). There were an additional 8 structural classes 
containing between 2 – 6 analogs and 22 structurally unique compounds.
CM037 was one of the structurally unique esterase activators that was found to be a potent 
and selective inhibitor of ALDH1A1 (IC50 = 4.6 ± 0.8 μM). A recent publication has shown 
that this compound, published as A37, is capable of disrupting spheroid formation in an 
ovarian cancer cell model by targeting ALDH1A1 activity[39]. These results show that this 
esterase-based HTS identified a novel compound selective for ALDH1A1 compared to 
ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 and that this compound could 
enter a cell and alter a cancer phenotype by inhibiting ALDH1A1[39]. Further studies of 
CM037 as well as the other compounds identified in this screen are needed.
Conclusion
Aldehyde dehydrogenases are critical enzymes involved in the metabolism of a variety of 
aldehyde substrates. ALDH1A1 has been identified as a marker for both normal and cancer 
stem cells and has been linked to such diseases as obesity, Parkinson’s disease, and cancer. 
Small molecule probes are urgently needed to elicit the role of this enzyme in both normal 
and disease states. However at this time there are no commercially available small 
molecules that selectively modulate ALDH1A1 activity compared to other ALDHs due to 
the high degree of structural and functional similarity, particularly within the ALDH1 
family. In this paper, we report the first structure of the human ALDH1A1 protein, 
complexed to NADH. As anticipated, ALDH1A1 is structurally similar to other ALDH 
proteins, particularly other ALDH1 family members, illustrating the difficulties in 
discovering selective modulators of this enzyme family. Also, we present an in vitro, 
esterase-based HTS that identified 256 compounds capable of modulating ALDH1A1 
esterase activity. Of these 256 hits, we examined the effect on aldehyde oxidation of 67 
compounds and nearly 50% (32 compounds) also modified aldehyde oxidation. These 
results indicate that the esterase activity of ALDH1A1 can be used to reliably identity small 
molecule modulators of the enzyme’s dehydrogenase activity. As presented, the HTS should 
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identify both activators and inhibitors of aldehyde oxidation. However, of the 57 esterase 
activators tested, none activated and 32 inhibited aldehyde oxidation. It is possible that an 
ALDH1A1 activator is present in the remaining compounds whose effect on aldehyde 
oxidation has yet to be tested. The screen was successful in identifying potent and selective 
inhibitors of ALDH1A1, with CM037 already characterized as a potent, selective inhibitor 
of ALDH1A1 capable of altering spheroid formation in an ovarian cancer cell model. Future 
work is needed on the remaining compounds identified in order to develop small molecule 
activators and inhibitors of ALDH1A1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Development of in vitro esterase-based HTS for discovery of modulators of 
ALDH1A1
• Identified 30 hits that selectively inhibited ALDH1A1 compared ALDH2 and 
ALDH3A1
• Determined first structure of human apo-ALDH1A1 and with its cofactor 
NADH
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Figure 1. 
Reactions used to discover ALDH1A1 modulators. A. NAD+-dependent aldehyde oxidation 
reaction monitored formation of NADH at 340 nm. B. HTS used an NAD+-independent 
esterase reaction that monitored the formation of p-nitrophenol at 405 nm.
Morgan and Hurley Page 14
Chem Biol Interact. Author manuscript; available in PMC 2016 June 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Structure of human ALDH1A1 (N121S) apo-enzyme. (A) Ribbon representation of the 
structure of the homotetrameric ALDH1A1 with each monomer colored separately. (B) 
Ribbon representation of an ALDH1A1 monomer showing the location of cysteine 303 in 
the active site plus the location of ALDH1A1 N121S used for the HTS (PDB Code 4WJ9).
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Figure 3. 
Structure of ALDH1A1 with reduced cofactor NADH. The location of the active site 
Cys-303 is shown in red. A. Surface rendition of NADH near the active site Cys-303. B 
Electron density maps of NADH with the original Fo – Fc in green contoured at 2.5 standard 
deviations and the final 2Fov – Fc map in grey contoured at 1.0 standard deviations.
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Figure 4. 
Overlap of the structure of ALDH1 A1 + NADH, in blue, with the structure of ALDH2 + 
NADH, in grey.
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Figure 5. 
Z-factor determination for esterase screen. Each point represents the rate of change in 
absorbance at 405 nm of a reaction. The x-axis is the column (1 – 24) on the 384-well plate 
of the reaction. The blue data points represent the enzyme + substrate (ES) control, with an 
average value of 4.086; the red is enzyme + substrate + inhibitor, with an average value of 
0.697; the open circles are the no enzyme control (blank). The lines represent 3× standard 
deviation from ES control (blue lines), ESI control (red lines), and blank (black lines). Each 
condition (ES, ESI, blank) performed on a separate plate with n = 384.
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Figure 6. 
Representative plate from esterase HTS. Each point represents one well, with the x-axis the 
column (1–24) on the plate and the y-axis, the rate of change measured at wavelength 405 
nm. Column 23 is the ES control, with an average value of 3.05 (n=16). Column 24 is the 
inhibition (ESI) control containing 25 μM Aldi-1. For this plate, an activator had a value ≥ 
6.1 while an inhibitor had a value ≤ 1.22. Lines are 3× standard deviation, blue for ES and 
red for ESI. On this plate, we identified 3 activators (P14, N16, M19) and 1 inhibitor (D12) 
out of 352 compounds, with labeling based on their row and column on 384-well plate.
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Figure 7. 
The effect on dehydrogenase activity of 67 compounds identified via an esterase HTS on 
three ALDH isoenzymes. The reactions used 20 μM compound and each bar represents 
mean/SEM (n = 3). Only one compound for ALDH3A1 and two compounds for ALDH2 
altered the respective activity of these enzymes more that 20%, while nearly half inhibited 
ALDH1A1 at least 50%.
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Figure 8. 
Surface topography of the cofactor binding site for ALDH1A1, ALDH2 (PDB 1O02), and 
ALDH3A1 (PDB 4L2O). The orange sphere in ALDH1A1 and ALDH2 represent cations, 
Yb for ALDH1A1 and Mg for ALDH2, that are present during crystallization.
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Table 1
Data collection and refinement statistics of ALDH1A1-NADH.
Data Collection
Apo-ALDH1A1 N121S
(PDB 4WJ9)
ALDH1A1-NADH Wild-type
(PDB 4WB9)
Space Group P422 P422
Cell Dimensions
 a,b,c [Å] 109, 109, 83 109, 109, 83
 α,β,γ [°] 90, 90, 90 90, 90, 90
Resolution [Å] 50 – 1.75 50 – 2.1
Rmerge 0.056 (0.59) 0.09 (0.52)
I/σi 31.5 (3.9) 17.8 (4.9)
Completeness [%] 99 (97) 99 (100)
Redundancy 9.6 (8.5) 8.3 (7.9)
Refinement
No. of Reflections 48862 29814
Rwork/Rfree 0.19/0.21 0.18/0.23
No. of Atoms
 Protein 3839 3837
 Ligand/Ions 2 50
 Water 246 215
R.M.S. Deviations
 Bond Lengths [Å] 0.010 0.017
 Bond Angles [°] 1.21 1.8
Numbers in parenthesis represent value of highest resolution shell.
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Table 2
IC50 values with ALDH1A1 for compounds that inhibit dehydrogenase activity.
Compound
IC50 [μM]
Structure
CM001
1.1 ± 0.1 *
CM009
5.3 ± 0.3 *
CM010
1.3 ± 0.1 *
CM020
0.45 ± 0.10
CM025
2.1 ± 0.7
CM026
0.80 ± 0.06
CM028
2.0 ± 0.1
CM037
4.6 ± 0.8
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Compound
IC50 [μM]
Structure
CM038
0.26 ± 0.01
CM039
0.41 ± 0.01
CM045
2.5 ± 0.5 *
CM047
0.31 ± 0.03 *
CM053
0.21 ± 0.04
CM055
0.24 ± 0.04
CM056
5.4 ± 0.8
CM057
0.92 ± 0.2
CM302
1.1 ± 0.1
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Compound
IC50 [μM]
Structure
CM306
3.5 ± 0.6
CM307
0.57 ± 0.09
Each value represents mean/SEM for three independent assays, each n = 3. Values calculated using 100 μM Propionaldehyde and 200 μM NAD+.
*
Maximum inhibition < 70%.
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Table 3
Structural classes of hit compounds
Structure HTS Hits
Dehydrogenase Activity
Tested Results
78 17 16 Inhibitors
20 3 CM001
10 1 No effect
9 0
13 1 No effect
11 4 3 Inhibitors
8 3 CM047
7 4 CM010
7 0
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Results of nine structural classes of esterase modulators representing 65% of the compounds identified from the esterase HTS.
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